In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...

The human skin map – which has been published in the journal Nature and is freely available here – is just one facet of the ...

An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in ...

Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its ...

At LSX in Boston last month, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at ...

Frontiers Health is back, bringing together healthcare innovators from around the world to exchange insights and discuss some ...

The pandemic served as a catalyst for a revolution in genomic surveillance for tracking pathogens. The technology proved ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics ...

Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...

Pfizer is already active in the protein degrader area, having partnered with Arvinas in a $2 billion-plus deal signed in 2021 ...